Search

Background: In China, depressive disorders have been estimated to be the second leading cause of years lived with disability (YLDs). However, nationally representative epidemiological data for depressive disorders, in particular depressed adults’ mental health services use, are still unavailable in China. The present study is a part of the Chinese National Mental Health Survey (CMHS), 2012–15, which reported the prevalence, treatment, and associated disability of depressive disorders in the Chinese general population. Methods: The CMHS recruited a representative sample of 28140 Chinese residents (≥ 18 years) by using multistage proportional-to-population-size sampling method. Trained investigators interviewed participants with the Composite International Diagnostic Interview 3.0 to ascertain the presence of lifetime and 12-month depressive disorders according to DSM-IV criteria, including major depressive disorder (MDD), dysthymic disorder (DD), and depressive disorder not otherwise specified (DD-NOS). Participants with 12-month depressive disorders were asked whether they ever received any 12-month treatment for their emotional problems and the specific types of treatment providers. The Quick Inventory of Depressive Symptomatology and Sheehan Disability Scale (SDS) were used to evaluate the severity of and role impairments associated with 12-month depressive symptoms. Findings: The weighted lifetime and 12-month prevalence rates of any depressive disorder were 6.8% (95%CI: 5.8-7.8%) and 3.6% (95%CI: 3.0-4.2%), respectively; the corresponding figures were 3.4% (95%CI: 2.0-3.9%) and 2.1% (95%CI: 1.8-2.4%) for MDD, 1.4% (95%CI: 1.1-1.7%) and 1.0% (95%CI: 0.8-1.3%) for DD, and 3.2% (95%CI: 2.6-3.9%) and 1.4% (95%CI: 1.1-1.7%) for DD-NOS. Overall, 77.2% of persons with 12-month depressive disorders had role impairment of any SDS domain: 82.2% for MDD, 81.5% for DD, and 64.6% for DD-NOS. Depressed participants reported an average of 41.0 days out of role in the past year due to depression; the corresponding figures were 49.7 days for MDD, 54.9 days for DD, and 12.2 days for DD-NOS. In total, 88.9% of individuals with 12-month depressive disorders had clinically significant depressive symptoms: 93.7% for MDD, 91.7% for DD, and 77.5% for DD-NOS. MDD and DD had similar proportions of “severe” or “very severe” depressive symptoms (43.0% and 42.1%), which were higher than DD-NOS (13.9%). 9.5% of participants with 12-month depressive disorders were treated in any treatment sector: 3.6% in the specialty mental health (SMH), 1.5% in the general medical (GM), 0.3% in the human services (HS), and 3.3% in the complementary-alternative medical (CAM) sector. Respondents with MDD and DYS had the highest proportion of seeking treatment in SMH sector (4.7% and 3.0%) while those with DD-NOS had the highest proportion of seeking treatment in CAM sector (most treatments were Traditional Chinese Medicine) (3.3%). Only 0.5% of participants with depressive disorders were treated adequately. Rates of treatment adequacy of MDD and DYS in SMH sector were 9.2% and 2.4%, respectively. Both rates in GM sector were 0%. Interpretation: Compared to western countries, our data show a relatively low prevalence of depressive disorders in China. Nevertheless, their associated role impairments, symptom severities, and disabilities are severe. Importantly, the treatment rates are rather low, let alone adequate treatment. Nationwide programs aiming at removing barriers in availability, accessibility, and acceptability to mental healthcare are needed in China. Funding: The study was funded by the Special Research Project for Non-profit Public Service of the Chinese Ministry of Health (grant number 201202022), the National Twelfth Five-Year Plan for Science and Technology Support of the Chinese Ministry of Science and Technology (grant numbers 2012BAI01B01 & 2015BAI13B00) and the National Key R&D Program of China (grant numbers 2017YFC0907800, 2017YFC0907801). Declaration of Interests: The authors have no conflicts of interest to declare Ethical Approval: The study protocol of CMHS was approved by the Ethics Committee of the Sixth Hospital of Peking University (No.: IMH-IRB-2013-13-1).

Background: Physical inactivity is an essential health-related behaviour and a significant risk factor for chronic non-communicable diseases. Temporal trends in physical inactivity in Chinese adults are unclear. Method: Four nationally representative cross-sectional surveys were conducted in 31 provinces in China between 2010 and 2018. Using a multi-stage, stratified, cluster-randomized sampling method, 669 919 Chinese adults were selected to participate in the surveys, and 645 903 adults were included in the analyses. Domain-specific (work-, transport-, and recreation-) moderate- to vigorous-intensity physical activity (MVPA) was measured using the Global Physical Activity Questionnaire. Physical activity was defined as not doing at least 150 minutes of moderate-intensity, 75 minutes of vigorous-intensity PA per week, or any equivalent combination of the two. Temporal changes in physical inactivity and no domain-specific PA were analyzed using linear regression methods. All analysis was accounted for the complex sampling design. Findings: From 2010 to 2018, the prevalence of physical inactivity among Chinese adults increased from 17·9% (95%CI, 16·3-19·5) to 22·3% (95%CI, 20·9-23·8) (Ptrend

Background: Recent studies have shown an increase in the prevalence of hyperuricemia (HUA) worldwide. However, representative national data suggesting national trends of HUA in China are lacking. Methods: Using a multi-stage, stratified, cluster-randomized sampling design, two cross-sectional surveys (representative of national and provincial information) were conducted in 31 provinces (autonomous regions and municipalities) in mainland China, with 166,861 Chinese adults in 2015–16 and 168,351 in 2018–19. Serum uric acid (SUA) levels of all participants were measured after a >10-hour overnight fast. HUA was defined when SUA was >420 μmol/L. Prevalence estimates were weighted to represent the total population considering the complex sampling design. Multivariable logistic regression models estimated factors associated with HUA. Findings: The overall HUA prevalence in the Chinese adult population was 11.1% (95% CI, 10.3–11.8%) in 2015–16 and 14.0% (95% CI, 13.1-14.8%) in 2018–19; an alarming rise was observed in the three years. HUA was more common in men with 19.3% (95% CI, 17.9–20.7%) in 2015–16 and 24.4% (95% CI, 23.0–25.8%) in 2018–19. The HUA prevalence also escalated from 2.8% (95% CI, 2.5-3.0%) in 2015–16 to 3.6% (95% CI, 3.2–4.0%) in 2018–19 in women. Various risk factors, including urban culture, settlement in the East, Zhuang descent, high education, heavy or frequent beer drinking, high red meat intake, physical inactivity, high BMI, central obesity, hypertension, hyperlipidemia, and low eGFR, were significantly associated with HUA. Interpretation: The estimated HUA prevalence among Chinese adults was 14.0% in 2018–19; significant escalating trends were observed between 2015 and 2019. Therefore, HUA is a public health problem in China. Funding: Chinese Central Government and National Key R&D Program of China. Declaration of Interest: We declare no competing interests. Ethical Approval: The ethical review committee of the Chinese Center for Disease Control and Prevention (China CDC) approved the 2015 CCDRFS (approval number 201519- A) and that of the National Center for Chronic and Noncommunicable Disease Control and Prevention, China CDC approved the 2018 CCDRFS (approval number 201819).